{ "schemaVersion": "deck-intelligence.v1", "id": "019de517-1302-72c9-b1b1-402f68725e8a", "slug": "8240d0b9060d59c07a4e5f5063c97322", "title": "Adagio Therapeutics | Results Presentation Deck | 11 slides", "subtitle": "Invivyd · 2023-11", "author": "Invivyd", "date": "2023-11-01 00:00:00", "pageCount": 11, "kind": "conference-presentation", "orientation": "landscape", "aspectRatio": 1.7777778, "document": { "id": "019de517-1302-72c9-b1b1-402f68725e8a", "slug": "8240d0b9060d59c07a4e5f5063c97322", "title": "Adagio Therapeutics | Results Presentation Deck | 11 slides", "rawTitle": "Adagio Therapeutics | Results Presentation Deck | 11 slides", "authorId": "adagio-therapeutics", "authorName": "Invivyd", "authorDisplay": "Invivyd", "kind": { "slug": "conference-presentation", "label": "Conference presentation" }, "sourceType": { "slug": "investor_relations", "label": "Investor relations" }, "fileName": "2023-11__adagio-therapeutics__results__8240d0b9.pdf", "sourceUrl": "https://www.slidebook.io/company/adagio-therapeutics/presentation/8240d0b9060d59c07a4e5f5063c97322/", "sourceDate": "2023-11-09 00:00:00", "presentationDate": "2023-11-01 00:00:00", "ingestedAt": "2026-05-01 19:49:47.993934+00", "status": "ready", "pageCount": 11, "orientation": "landscape", "aspectRatio": 1.7777778, "targetCompany": null, "targetTicker": null, "metadata": { "corpus": "slidebook", "industry": null, "local_root": "/Users/miguelsuredasuau/Desktop/lalalalla/_scrape/slidebook/decks/2023-11__adagio-therapeutics__results__8240d0b9", "image_width": 1920, "image_format": "jpg", "deck_type_raw": "Results Presentation Deck", "deck_type_slug": "results", "source_url_pattern": "https://www.slidebook.io/company/{company_slug}/presentation/{deck_id}/" } }, "coverage": { "pageCount": 11, "pagesIndexed": 11, "pagesWithImages": 11, "pagesWithMetadata": 11, "imageCoveragePct": 100, "metadataCoveragePct": 100, "componentCount": 49, "chartCount": 1, "metricSlides": 0, "toolMatches": 3, "documentToolMatches": 0, "frameworkMatches": 0, "arcMatches": 1, "beatMatches": 4, "loopMatches": 2, "patternMatches": 0, "storymakersMatch": false, "scoreAvailable": false, "reviewAvailable": false, "activistThesisAvailable": false, "pitchdeckMetadataAvailable": false, "pitchdeckProfileAvailable": false }, "blocks": [], "matches": { "arcs": [ { "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "evidence": "The presentation follows a clear sequence of attention, need, visualization, and action", "isPrimary": true, "confidence": 0.8, "extraction": { "at": "2026-07-16 23:11:44.70423+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "beats": [ { "to": 1, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 1, "name": "Attention", "beatId": "17abe961-122f-4b8b-82a5-50aa5dce53c4", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Attention", "slug": "monroes-sequence-attention", "status": "active", "canonId": "019dd9b8-1573-779d-93ca-6174bbd57938", "version": 1, "description": null }, "evidence": "The cover slide grabs attention with a clear title and agenda", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Hook", "slug": "hook", "status": "active", "canonId": "019dd9b8-01a6-7328-bff2-b22eb40b3ea5", "version": 1, "description": "The opener — a deliberate move to earn attention before any argument. Used by AIDA, Monroes, Pixar Pitch, Overcoming the Monster." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 5, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 5, "name": "Need", "beatId": "b55d8bab-3721-421b-b288-fbc544a321e0", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Need", "slug": "monroes-sequence-need", "status": "active", "canonId": "019dd9b8-160b-710a-b2d6-2bafabd78694", "version": 1, "description": null }, "evidence": "The problem statement highlights the urgent need for protection against COVID-19", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 7, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 6, "name": "Visualization", "beatId": "98297a7b-21bb-4330-add0-fea6bdafb33b", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Visualization", "slug": "monroes-sequence-visualization", "status": "active", "canonId": "019dd9b8-1786-777e-b185-480585cc47fd", "version": 1, "description": null }, "evidence": "The comparison table and roadmap provide a clear visualization of VYD222's potential", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 }, { "to": 10, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null, "categoryName": "Strategy & Business", "categorySlug": "strategy-business" }, "from": 9, "name": "Action", "beatId": "feb56317-a2e6-4f8a-8b39-db8ce0bbaf5d", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Action", "slug": "monroes-sequence-action", "status": "active", "canonId": "019dd9b8-181e-760d-befc-010c2424fa89", "version": 1, "description": null }, "evidence": "The commercialization preparations and financial overview outline the next steps", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889", "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction", "position": 0, "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:11:44.892947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } }, { "to": 3, "from": 1, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null, "categoryName": "Urgency", "categorySlug": "urgency" }, "matchId": "70ae55fa-de1b-4bab-93c4-6903f1924753", "evidence": "The presentation provides an overview of the current situation and the urgency of the need", "position": 1, "objective": "Why is now the right time for VYD222?", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:11:44.928857+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "76117368-e337-4cf1-a65d-c3e6daecaeec", "evidence": "list/bullet: Company continues to advance INVYMAB™, its proprietary platform approach designed for rapid, serial generation of new antibodies to address viral threats", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 01:54:03.140789+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null }, { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "478efb00-635d-4412-b6bc-5ad4d1413924", "evidence": "title/action-title: Despite the availability of vaccines, immunocompromised people remain at higher risk for severe COVID-19 outcomes and need additional therapeutic options to protect against COVID-19", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.8, "extraction": { "at": "2026-07-17 01:54:03.269172+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "20ea3e97-172c-45ab-9254-18d32c0a64ee", "evidence": "Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study¹", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 01:54:03.224862+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "patterns": [] }, "storymakers": null, "score": null, "review": null, "activistThesis": null, "pitchdeck": { "metadata": null, "profile": null }, "slides": [ { "page": 1, "type": "setup", "function": "front_matter", "imagePath": "https://imgproxy.kitesheet.com/khaFKwER3MtKnWKouiYxylqSfUUuHoCYyxLGE2ceveY/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MjQwZDBiOTA2MGQ1OWMwN2E0ZTVmNTA2M2M5NzMyMi9wMDAxLmpwZw", "rawType": "cover", "block": null, "metadata": { "slideType": "cover", "slideTypeCanon": { "name": "Cover", "slug": "cover", "status": "active", "canonId": "019de52d-05f2-729d-9f93-e0504f0a2410", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 32, "componentCount": 4, "textChars": 238, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:52.901+00", "seconds": 4.214, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/1", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-1", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.045, "w": 0.165, "x": 0.7616667, "y": 0.083333336 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:52.901+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88de6bc7-1844-4e23-8294-a32be4abd125", "parentComponentId": null }, { "bbox": { "h": 0.033333335, "w": 0.26666668, "x": 0.41666666, "y": 0.6416667 }, "kind": "paragraph", "text": "November 9, 2023", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:52.901+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3cc4a9ce-0a82-42c9-a248-62b6a0aa9c1f", "parentComponentId": null }, { "bbox": { "h": 0.033333335, "w": 0.48333335, "x": 0.49166667, "y": 0.925 }, "kind": "source-note", "text": "2023 Invivyd, Inc. Invivyd and the Invivyd logo are trademarks of Invivyd, Inc.\nAll trademarks in this presentation are the property of their respective owners.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:52.901+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b765c0fd-5b17-47bd-80d6-a5aca4dc794e", "parentComponentId": null }, { "bbox": { "h": 0.13333334, "w": 0.55, "x": 0.41666666, "y": 0.48333335 }, "kind": "title", "text": "INVIVYD Q3 2023 FINANCIAL\nRESULTS & BUSINESS HIGHLIGHTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:52.901+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d7a84ada-3cbc-4231-b43e-7c5a96abe683", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 1, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null }, "from": 1, "name": "Attention", "beatId": "17abe961-122f-4b8b-82a5-50aa5dce53c4", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Attention", "slug": "monroes-sequence-attention", "status": "active", "canonId": "019dd9b8-1573-779d-93ca-6174bbd57938", "version": 1, "description": null }, "evidence": "The cover slide grabs attention with a clear title and agenda", "position": 0, "isPrimaryArc": true, "parentBeatType": { "name": "Hook", "slug": "hook", "status": "active", "canonId": "019dd9b8-01a6-7328-bff2-b22eb40b3ea5", "version": 1, "description": "The opener — a deliberate move to earn attention before any argument. Used by AIDA, Monroes, Pixar Pitch, Overcoming the Monster." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 3, "from": 1, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "70ae55fa-de1b-4bab-93c4-6903f1924753", "evidence": "The presentation provides an overview of the current situation and the urgency of the need", "position": 1, "objective": "Why is now the right time for VYD222?", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:11:44.928857+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "thumbSrc": "https://imgproxy.kitesheet.com/yLb--Xd0YO0Z4SdR4XvvmEqXrhBZN3XlrY-Rd7GSNdA/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MjQwZDBiOTA2MGQ1OWMwN2E0ZTVmNTA2M2M5NzMyMi9wMDAxLmpwZw", "imagePathAlt": "https://imgproxy.kitesheet.com/SfkUTE3V12q42xmbgHm5KTxCs_-wJFy04Q5k-Py1dq8/rs:fit:1200:1200:0/q:82/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MjQwZDBiOTA2MGQ1OWMwN2E0ZTVmNTA2M2M5NzMyMi9wMDAxLnBuZw", "thumbSrcAlt": "https://imgproxy.kitesheet.com/P19fiBtBpG7chWzBB5jf1Dug6I0rzKzT1QBYYOnbUiY/rs:fit:480:480:0/q:78/f:webp/czM6Ly9raXRlc2hlZXQvY29ycHVzL3NsaWRlcy84MjQwZDBiOTA2MGQ1OWMwN2E0ZTVmNTA2M2M5NzMyMi9wMDAxLnBuZw" }, { "page": 2, "type": "setup", "function": "front_matter", "rawType": "disclaimer", "block": null, "metadata": { "slideType": "disclaimer", "slideTypeCanon": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "019de52d-0801-727b-b98a-5ed095aeee78", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "balanced", "densityScore": 47, "componentCount": 3, "textChars": 4975, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:56.16+00", "seconds": 7.338, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/2", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-2", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.609, "w": 0.91, "x": 0.045, "y": 0.204 }, "kind": "disclaimer", "text": "This presentation contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Statements in this presentation that are not statements of historical fact are forward-looking statements. Words such as \"may,\" \"will,\" \"should,\" \"expect,\" \"plan,\" \"anticipate,\" \"seek,\" \"could,\" \"intend,\" \"target,\" \"aim,\" \"project,\" \"designed to,\" \"estimate,\" \"believe,\" \"predict,\" \"potential\" or \"continue\" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements include statements concerning, among other things, the progress and timing of our ongoing research and clinical development activities, including with respect to VYD222; the timing of anticipated initial primary endpoint data from our CANOPY Phase 3 pivotal clinical trial; our expectation to rapidly generate clinical data for a potential VYD222 emergency use authorization (EUA) submission; our plans to submit an application for EUA in the U.S. as soon as practicable; whether we are able to successfully submit an EUA in the future, and the outcome of any such EUA submission; the company's expectations regarding the size of target patient populations and the potential market opportunity for its product candidates; the potential of the company's INVYMAB platform approach to rapidly, serially generate new antibodies to address viral threats; our beliefs regarding the need of immunocompromised people for additional therapeutic options to protect against COVID-19; the future of the COVID-19 landscape; our expectations regarding the size of target patient populations and the potential market opportunity for our product candidates, as well as our market position; the CANOPY clinical trial design; the potential commercialization of VYD222 in the U.S., if authorized; our belief that our existing cash resources will be sufficient to support an expected cash runway into the fourth quarter of 2024; and other statements that are not historical fact. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements and you should not place undue reliance on our forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause our actual results to differ materially from the results described in or implied by the forward-looking statements, including, without limitation: the timing and progress of our discovery, preclinical and clinical development activities; our ability to rapidly generate the data needed from the CANOPY clinical trial to support a potential EUA submission for VYD222; whether we are able to successfully submit an EUA in the future, and the outcome of any such EUA submission; unexpected safety or efficacy data observed during preclinical studies or clinical trials; the predictability of clinical success of VYD222 or other product candidates based on neutralizing activity in preclinical studies; potential variability in neutralizing activity of product candidates tested in different assays, such as pseudovirus assays and authentic assays; the risk that results of preclinical studies or clinical trials may not be predictive of future results in connection with current or future clinical trials; variability of results in models used to predict activity against SARS-CoV-2 variants of concern; changes in expected or existing competition; changes in the regulatory environment; the uncertainties and timing of the regulatory approval process; whether our platform approach enables us to rapidly, serially generate new antibodies to address viral threats; whether VYD222 or any other product candidate is able to demonstrate and sustain neutralizing activity against predominant SARS-CoV-2 variants, particularly in the face of viral evolution; and whether we have adequate funding to meet future operating expenses and capital expenditure requirements. Other factors that may cause our actual results to differ materially from those expressed or implied in the forward-looking statements in this presentation are described under the heading \"Risk Factors\" in our most recent Annual Report on Form 10-K for the year ended December 31, 2022 filed with the Securities and Exchange Commission (SEC), and in our other filings with the SEC, and in our future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this presentation are made as of this date, and we undertake no duty to update such information whether as a result of new information, future events or otherwise, except as required under applicable law.", "attrs": null, "canon": { "kind": { "name": "Disclaimer", "slug": "disclaimer", "status": "active", "canonId": "91173477-d91f-4024-bbaf-d4f93e3f82dc", "version": 1, "description": "Legal/cautionary text that occupies most of the body of its slide." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:56.16+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "0acdefa9-d450-4f82-b98d-532325c8c3e4", "parentComponentId": null }, { "bbox": { "h": 0.036, "w": 0.869, "x": 0.045, "y": 0.84 }, "kind": "source-note", "text": "© 2023 Invivyd, Inc. Invivyd, Invymab and the Invivyd logo are trademarks of Invivyd, Inc. All trademarks in this presentation are the property of their respective owners.", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:56.16+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "083b4716-0a0d-4043-b26a-d9af846b00e4", "parentComponentId": null }, { "bbox": { "h": 0.105, "w": 0.72, "x": 0.045, "y": 0.049 }, "kind": "title", "text": "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:56.16+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d02109ee-4bcd-4b16-bd35-9d74b6266e0a", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 3, "from": 1, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "70ae55fa-de1b-4bab-93c4-6903f1924753", "evidence": "The presentation provides an overview of the current situation and the urgency of the need", "position": 1, "objective": "Why is now the right time for VYD222?", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:11:44.928857+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 3, "type": "setup", "function": "front_matter", "rawType": "agenda", "block": null, "metadata": { "slideType": "agenda", "slideTypeCanon": { "name": "Agenda", "slug": "agenda", "status": "active", "canonId": "019de52d-061b-7470-b138-3ffa5e612cce", "version": 1, "description": null }, "function": "front_matter", "functionCanon": { "name": "Front matter", "slug": "front_matter", "status": "active", "canonId": "019de52d-133d-73f0-9e26-201eda96b098", "version": 1, "description": null }, "density": "sparse", "densityScore": 23, "componentCount": 2, "textChars": 341, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:51.848+00", "seconds": 2.989, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/3", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-3", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.58, "w": 0.64, "x": 0.043, "y": 0.227 }, "kind": "list", "text": "1. Introduction/Overview\n– Dave Hering, Chief Executive Officer\n2. CANOPY Trial & Latest VYD222 In Vitro Neutralizing Data\n– Pete Schmidt, M.D., Chief Medical Officer\n3. Market Opportunity & Commercial Preparations\n– Jeremy Gowler, Chief Operating & Commercial Officer\n4. Q3 Financial Review\n– Bill Duke, Chief Financial Officer\n5. Q&A", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Numbered list", "slug": "numbered", "status": "active", "canonId": "019de52c-fcc0-7718-a284-a4250c805df2", "version": 1, "description": null }, "framework": null }, "subkind": "numbered", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:51.848+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "88d4e45f-b172-4e3f-a684-058b7074eb1e", "parentComponentId": null }, { "bbox": { "h": 0.036, "w": 0.139, "x": 0.043, "y": 0.106 }, "kind": "title", "text": "AGENDA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:51.848+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "23156e0c-9186-4301-95e3-1a3fd7d3e9b5", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 3, "from": 1, "loop": { "name": "15_why_now", "slug": "15-why-now", "status": "active", "bestFor": "Sales pitches, fundraising, requesting immediate budget approval", "canonId": "019dd956-6c00-70cd-bd42-6bacc4af726f", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Context (Trends) -> The Trigger Event -> The Window of Opportunity", "description": "Create temporal urgency by proving that the window of opportunity is opening or closing", "familyLabel": null }, "matchId": "70ae55fa-de1b-4bab-93c4-6903f1924753", "evidence": "The presentation provides an overview of the current situation and the urgency of the need", "position": 1, "objective": "Why is now the right time for VYD222?", "confidence": 0.6, "extraction": { "at": "2026-07-16 23:11:44.928857+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 4, "type": "setup", "function": "summarize", "rawType": "key_messages", "block": null, "metadata": { "slideType": "key_messages", "slideTypeCanon": { "name": "Key messages", "slug": "key_messages", "status": "active", "canonId": "019de52d-0712-703f-89f5-bda6688faf3f", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "dense", "densityScore": 70, "componentCount": 6, "textChars": 530, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:53.927+00", "seconds": 4.898, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/4", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-4", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.06, "w": 0.783, "x": 0.104, "y": 0.268 }, "kind": "list", "text": "Enrollment completed in CANOPY Phase 3 pivotal clinical trial investigating VYD222 for the prevention of symptomatic COVID-19", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.927+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3d5ee62e-85db-410e-a941-ec2228591167", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.783, "x": 0.104, "y": 0.584 }, "kind": "list", "text": "Company aims to submit an application for Emergency Use Authorization (EUA) in the U.S. as soon as practicable", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.927+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "7eb2a733-70ba-445d-9ab7-f978c399453d", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.783, "x": 0.104, "y": 0.426 }, "kind": "list", "text": "Company expects to have initial CANOPY primary endpoint data by late 2023 or early Q1 2024", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.927+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bf588f85-57a9-42a5-8e4e-15b196652519", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.783, "x": 0.104, "y": 0.742 }, "kind": "list", "text": "Company continues to advance INVYMAB™, its proprietary platform approach designed for rapid, serial generation of new antibodies to address viral threats", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.927+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c33c760e-538f-4f4d-b8aa-c76205647f76", "parentComponentId": null }, { "bbox": { "h": 0.016, "w": 0.076, "x": 0.86, "y": 0.95 }, "kind": "source-note", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.927+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b2b4baf9-1ec5-4ccc-bfb8-0cdd7e526c82", "parentComponentId": null }, { "bbox": { "h": 0.029, "w": 0.727, "x": 0.045, "y": 0.102 }, "kind": "title", "text": "RECENT BUSINESS HIGHLIGHTS & KEY ACHIEVEMENTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.927+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2893cd74-a345-48c5-8609-c7483e59594d", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "List presentation", "slug": "list-presentation", "status": "active", "bestFor": null, "canonId": "019dd9e1-4ef7-777d-ba68-9074c2b3bcf1", "version": 1, "bodyDocId": null, "description": "Bulleted, numbered, or checklist enumerations.", "familyLabel": null, "categoryName": null, "categorySlug": null }, "agent": null, "layer": "slide", "agents": null, "matchId": "76117368-e337-4cf1-a65d-c3e6daecaeec", "evidence": "list/bullet: Company continues to advance INVYMAB™, its proprietary platform approach designed for rapid, serial generation of new antibodies to address viral threats", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.9, "extraction": { "at": "2026-07-17 01:54:03.140789+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 4, "whyItWorks": null, "antipattern": null, "cardinality": "common", "narrativePurpose": null } ], "frameworks": [], "arcBeats": [], "loops": [], "locked": true }, { "page": 5, "type": "tension", "function": "diagnose_problem", "rawType": "problem_statement", "block": null, "metadata": { "slideType": "problem_statement", "slideTypeCanon": { "name": "Problem statement", "slug": "problem_statement", "status": "active", "canonId": "019de52d-0879-768d-bba8-8da8a5a121d4", "version": 1, "description": null }, "function": "diagnose_problem", "functionCanon": { "name": "Diagnose problem", "slug": "diagnose_problem", "status": "active", "canonId": "019de52d-176d-761f-b608-cf52262d2ab2", "version": 1, "description": null }, "density": "dense", "densityScore": 73, "componentCount": 5, "textChars": 1430, "nDataPoints": 12, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:54.785+00", "seconds": 5.571, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/5", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-5", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.445, "w": 0.369, "x": 0.574, "y": 0.242 }, "kind": "list", "text": "Assessing the risk and costs of COVID-19 in immunocompromised populations in a large United States commercial insurance health plan: the EPOCH-US Study²\nIn a sample of ~17M people in a large U.S. commercial health insurance plan, 2.7% were IC\n~14% of the IC people were diagnosed with COVID-19 and, of those, 24% were hospitalized\nIC people had long hospital stays and high costs associated with COVID-19, with a mean cost of $64,029 per patient and mean length of hospitalization stay of 15 days", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.785+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9dc15908-07d9-4974-90dd-bf78d40f0b7b", "parentComponentId": null }, { "bbox": { "h": 0.502, "w": 0.42, "x": 0.064, "y": 0.242 }, "kind": "list", "text": "Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study¹\nIn a sample of ~12M people in England, 3.9% were immunocompromised (IC)\nAlthough only 3.9% of the population, IC people accounted for 22% of COVID-19 hospitalizations and 24% of COVID-19 deaths – even though >80% of the IC population had received ≥3 COVID-19 vaccines\nCertain IC people (e.g., solid organ and stem cell transplant recipients and those recently treated for blood cancers), had greater than 10-fold increases in risk compared to those without these conditions", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.785+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "d46866a2-e795-4e1b-8c46-da47554fde27", "parentComponentId": null }, { "bbox": { "h": 0.013, "w": 0.44, "x": 0.045, "y": 0.954 }, "kind": "source-note", "text": "1. Evans Lancet Reg 2023; 2. Ketkar Curr Med Res Opin 2023", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.785+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "3928d1a4-9c94-4e97-8769-520331898d31", "parentComponentId": null }, { "bbox": { "h": 0.069, "w": 0.894, "x": 0.055, "y": 0.83 }, "kind": "title", "text": "Despite the availability of vaccines, immunocompromised people remain at higher risk for severe COVID-19 outcomes and need additional therapeutic options to protect against COVID-19", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.785+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f8d12e83-5b5d-42c1-84ae-6cf88be356a3", "parentComponentId": null }, { "bbox": { "h": 0.09, "w": 0.899, "x": 0.045, "y": 0.06 }, "kind": "title", "text": "THE NEED TO PROTECT IMMUNOCOMPROMISED INDIVIDUALS FROM COVID-19 IS CLEAR AND URGENT", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.785+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2f6c7531-2504-4c24-82f4-64514458e62b", "parentComponentId": null } ], "metrics": [], "tools": [ { "tool": { "name": "Action Titles", "slug": "action-titles", "status": "active", "bestFor": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "canonId": "019dd956-ac70-700b-a608-ba58e78f5dcc", "version": 1, "bodyDocId": "816dad3c-9983-41c1-a86e-978ebd582841", "description": "The McKinsey-bred discipline of writing every slide title as a complete declarative sentence with a verb and an insight, not a topic label. Each title is a sub-claim that ladders up to the deck's governing thought; read in sequence, the titles reconstruct the executive summary.", "familyLabel": null, "categoryName": "Slide", "categorySlug": "slide" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "478efb00-635d-4412-b6bc-5ad4d1413924", "evidence": "title/action-title: Despite the availability of vaccines, immunocompromised people remain at higher risk for severe COVID-19 outcomes and need additional therapeutic options to protect against COVID-19", "pageRefs": null, "priority": "Core", "whenToUse": "Any decision-grade deliverable — strategy recommendation, board update, investment memo, M&A review, post-mortem — where the reader is being asked to agree, decide, or act and will skim the title bar at speed.", "confidence": 0.8, "extraction": { "at": "2026-07-17 01:54:03.269172+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": "Solves two failure modes at once. (1) The buried claim: action titles place the conclusion on the page before any analysis is read, so a busy reader doesn't reverse-engineer it from the chart. (2) The spineless deck: because each title is a claim, slides have to ladder up to the governing thought; logical gaps become visible as topic-shaped titles in a sequence that no longer reads as a story.", "antipattern": "Topic labels disguised as titles — Volume by quarter, Key findings, Pricing strategy, Margins have been impacted. No verb, or a passive verb with no agent, or a fact (Revenue grew 12%) without the so-what. Also: titles that overreach the chart's evidence, multi-claim X-grew-but-Y-fell welded titles, and mechanical repetition of the same X-drove-Y template across the deck.", "cardinality": null, "narrativePurpose": "Forces the deck to carry its argument in the title bar so a senior reader can extract the recommendation without opening a single slide; converts a binder of topics into a navigable pyramid where every slide is a node defending the apex." }, { "tool": { "name": "Problem Statement Canvas", "slug": "problem-statement-canvas", "status": "active", "bestFor": null, "canonId": "019dd956-839d-744b-ad11-9bf3e3642a18", "version": 1, "bodyDocId": null, "description": "Structured definition of the problem: What? Who? Where? When? Scale?", "familyLabel": null, "categoryName": "Block", "categorySlug": "block" }, "agent": "Architect", "layer": "slide", "agents": [ "Architect" ], "matchId": "20ea3e97-172c-45ab-9254-18d32c0a64ee", "evidence": "Impact of COVID-19 on immunocompromised populations during the Omicron era: insights from the observational population-based INFORM study¹", "pageRefs": null, "priority": null, "whenToUse": null, "confidence": 0.7, "extraction": { "at": "2026-07-17 01:54:03.224862+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": null }, "pageNumber": 5, "whyItWorks": null, "antipattern": null, "cardinality": null, "narrativePurpose": null } ], "frameworks": [], "arcBeats": [ { "to": 5, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null }, "from": 5, "name": "Need", "beatId": "b55d8bab-3721-421b-b288-fbc544a321e0", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Need", "slug": "monroes-sequence-need", "status": "active", "canonId": "019dd9b8-160b-710a-b2d6-2bafabd78694", "version": 1, "description": null }, "evidence": "The problem statement highlights the urgent need for protection against COVID-19", "position": 1, "isPrimaryArc": true, "parentBeatType": { "name": "Complication", "slug": "complication", "status": "active", "canonId": "019dd9b8-0275-7709-b2d6-4f77c3fc7579", "version": 1, "description": "The point in the narrative where the audience should feel discomfort. Required for argumentative arcs." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889", "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction", "position": 0, "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:11:44.892947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 6, "type": "analysis", "function": "analyze_data", "rawType": "comparison_table", "block": null, "metadata": { "slideType": "comparison_table", "slideTypeCanon": { "name": "Comparison table", "slug": "comparison_table", "status": "active", "canonId": "019de52d-0a06-73f8-8813-fe022fab1de2", "version": 1, "description": null }, "function": "analyze_data", "functionCanon": { "name": "Analyze data", "slug": "analyze_data", "status": "active", "canonId": "019de52d-1590-7413-8c82-cc218cff40b4", "version": 1, "description": null }, "density": "dense", "densityScore": 68, "componentCount": 5, "textChars": 733, "nDataPoints": 10, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:53.865+00", "seconds": 4.482, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/6", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-6", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.17, "w": 0.402, "x": 0.049, "y": 0.704 }, "kind": "callout", "text": "XBB.1.5.10 and EG.5 (one of the dominant variants in the U.S.) are XBB variants with the same spike glycoprotein sequence, including the F456L mutation found in ~80% of the current CDC-tracked variants2-3", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.865+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "934280e6-c936-477b-b0a4-94ca689207e9", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.34, "x": 0.52, "y": 0.94 }, "kind": "legend", "text": "✓ Neutralizing activity in standardized in vitro assays", "attrs": null, "canon": { "kind": { "name": "Legend", "slug": "legend", "status": "active", "canonId": "31361933-3d22-4c70-bbad-0801e9fffc0c", "version": 1, "description": "Color/symbol decoder placed adjacent to a chart or diagram." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.865+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b7ddccb7-5ca9-4767-8c63-70028295a5b9", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.44, "x": 0.049, "y": 0.923 }, "kind": "source-note", "text": "References: 1. VYD222 data generated by CRO using a pseudovirus SARS-CoV-2 neutralizing antibody assay; 2. https://covid.cdc.gov/covid-data-tracker/#variant-proportions (accessed Oct 30, 2023); 3. covSPECTRUM.org", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.865+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4e68528c-5bfe-431b-b04f-10b632f78438", "parentComponentId": null }, { "bbox": { "h": 0.65, "w": 0.784, "x": 0.107, "y": 0.201 }, "kind": "table", "text": "VARIANT\nWT(D614G)\nDelta\nOmicron\nSUBLINEAGE\nWT(D614G)\nB.1.617.2\nBA.1\nBA.4/5\nBA.4.6\nBF.7\nXBB.1\nXBB.1.5\nXBB.1.16\nXBB.1.5.10/EG.5\nVYD2221\n✓\n✓\n✓\n✓\n✓\n✓\n✓\n✓\n✓\n✓", "attrs": null, "canon": { "kind": { "name": "Table", "slug": "table", "status": "active", "canonId": "019de52c-f9c8-7148-8119-eaac9594cd28", "version": 1, "description": "Tabular data layout." }, "tool": null, "subkind": { "name": "Data table", "slug": "data", "status": "active", "canonId": "019de52d-02d5-75b8-8abf-88e92bf63569", "version": 1, "description": null }, "framework": null }, "subkind": "data", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.865+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fb3f93c5-52d2-45a8-bc2d-89da344e6536", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.91, "x": 0.042, "y": 0.06 }, "kind": "title", "text": "VYD222 HAS DEMONSTRATED BROAD IN VITRO NEUTRALIZING ACTIVITY AGAINST VARIOUS PRE-OMICRON AND OMICRON VARIANTS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.865+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "facb06d8-7ef8-48ec-bd2e-7c348d21f1df", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null }, "from": 6, "name": "Visualization", "beatId": "98297a7b-21bb-4330-add0-fea6bdafb33b", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Visualization", "slug": "monroes-sequence-visualization", "status": "active", "canonId": "019dd9b8-1786-777e-b185-480585cc47fd", "version": 1, "description": null }, "evidence": "The comparison table and roadmap provide a clear visualization of VYD222's potential", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889", "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction", "position": 0, "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:11:44.892947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 7, "type": "resolution", "function": "plan_implementation", "rawType": "roadmap", "block": null, "metadata": { "slideType": "roadmap", "slideTypeCanon": { "name": "Roadmap", "slug": "roadmap", "status": "active", "canonId": "019de52d-0a55-72bc-9b7b-a47ef109839c", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 82, "componentCount": 7, "textChars": 789, "nDataPoints": 6, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:54.743+00", "seconds": 5.348, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/7", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-7", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.23, "w": 0.62, "x": 0.32, "y": 0.63 }, "kind": "diagram", "text": "2:1 Randomization VYD222 4500 mg IV (n=300) Day 1 (Dosing) Placebo IV (n=150) Month 3 (Redosing) Month 12 (Last visit)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.743+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "49b9a0e8-8740-4a89-abe8-acf05afcbc68", "parentComponentId": null }, { "bbox": { "h": 0.23, "w": 0.62, "x": 0.32, "y": 0.26 }, "kind": "diagram", "text": "Open Label VYD222 4500 mg IV (n=300) Day 1 (Dosing) Day 28 (Primary efficacy endpoint) Month 3 (Redosing) Month 12 (Last visit)", "attrs": null, "canon": { "kind": { "name": "Diagram", "slug": "diagram", "status": "active", "canonId": "019de52c-f9f0-734a-81de-15382ff28c65", "version": 1, "description": "Schematic or relational diagram." }, "tool": null, "subkind": { "name": "Timeline", "slug": "timeline", "status": "active", "canonId": "019de52d-03c5-73fc-84aa-4180cbf0f5cf", "version": 1, "description": null }, "framework": null }, "subkind": "timeline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.743+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "65a25ad2-f4dd-4663-8659-58e7cbbeacae", "parentComponentId": null }, { "bbox": { "h": 0.159, "w": 0.269, "x": 0.045, "y": 0.69 }, "kind": "list", "text": "COHORT B At risk of SARS-CoV-2 exposure (N=450) Primary endpoint: Safety/tolerability", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.743+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "6d9c17c3-5bc1-44a4-a853-238f423afcd2", "parentComponentId": null }, { "bbox": { "h": 0.259, "w": 0.269, "x": 0.045, "y": 0.315 }, "kind": "list", "text": "COHORT A Immunocompromised (N=300) Primary endpoints: Safety/tolerability Day 28 serum neutralizing titers (calculated from the pharmacokinetic concentrations of VYD222 and the IC50 value for VYD222 against relevant SARS-CoV-2 variants)", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.743+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "fe3bdfb4-fd77-46da-936f-11b147c90dcd", "parentComponentId": null }, { "bbox": { "h": 0.013, "w": 0.32, "x": 0.045, "y": 0.95 }, "kind": "source-note", "text": "Source: ClinicalTrials.gov Identifier: NCT06039449; IV, intravenous", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.743+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "087c3502-26a4-45d2-8f94-884340d05ece", "parentComponentId": null }, { "bbox": { "h": 0.022, "w": 0.39, "x": 0.045, "y": 0.199 }, "kind": "title", "text": "The CANOPY clinical trial is now fully enrolled", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Action title", "slug": "action-title", "status": "active", "canonId": "019de52c-fb31-734c-a0f5-a3935b73135d", "version": 1, "description": null }, "framework": null }, "subkind": "action-title", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.743+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "c4af0f8f-39c1-4642-aa9c-1312a873892d", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.91, "x": 0.045, "y": 0.06 }, "kind": "title", "text": "THE CANOPY PHASE 3 CLINICAL TRIAL OF VYD222 IS DESIGNED TO RAPIDLY GENERATE CLINICAL DATA FOR A POTENTIAL EUA", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.743+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9f467fbb-4e23-4a46-a6b9-18702ac11e0d", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 7, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null }, "from": 6, "name": "Visualization", "beatId": "98297a7b-21bb-4330-add0-fea6bdafb33b", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Visualization", "slug": "monroes-sequence-visualization", "status": "active", "canonId": "019dd9b8-1786-777e-b185-480585cc47fd", "version": 1, "description": null }, "evidence": "The comparison table and roadmap provide a clear visualization of VYD222's potential", "position": 2, "isPrimaryArc": true, "parentBeatType": { "name": "Evidence", "slug": "evidence", "status": "active", "canonId": "019dd9b8-03f9-772a-b84a-4f07b415b77a", "version": 1, "description": "A dedicated proof beat exists in only ~4 arcs (Gambit, Sequoia, AIDA, Monroes). Other arcs embed evidence inline within development." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889", "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction", "position": 0, "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:11:44.892947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 8, "type": "resolution", "function": "size_opportunity", "rawType": "market_sizing", "block": null, "metadata": { "slideType": "market_sizing", "slideTypeCanon": { "name": "Market sizing", "slug": "market_sizing", "status": "active", "canonId": "019de52d-08c8-756c-8664-733b73a7ee7b", "version": 1, "description": null }, "function": "size_opportunity", "functionCanon": { "name": "Size opportunity", "slug": "size_opportunity", "status": "active", "canonId": "019de52d-147b-7568-8828-a74a27697618", "version": 1, "description": null }, "density": "overcrowded", "densityScore": 78, "componentCount": 6, "textChars": 874, "nDataPoints": 7, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:54.915+00", "seconds": 5.243, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/8", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-8", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.63, "w": 0.66, "x": 0.04, "y": 0.27 }, "kind": "chart", "text": "4M (e.g., early-stage kidney disease, virally-suppressed HIV); 3M (e.g., non-hematologic cancer, IBD, MS); 2M (e.g., RA, primary immunodeficiency diseases); 485K", "attrs": null, "canon": { "kind": { "name": "Chart", "slug": "chart", "status": "active", "canonId": "019de52c-f9a0-76ef-adc6-0b859109d1f8", "version": 1, "description": "Quantitative chart." }, "tool": null, "subkind": { "name": "Bubble chart", "slug": "bubble", "status": "active", "canonId": "019de52d-00a4-756f-8978-8d5e48905dbc", "version": 1, "description": null }, "framework": null }, "subkind": "bubble", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.915+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4017dbb2-9ea3-4965-a613-baef1f9037d3", "parentComponentId": null }, { "bbox": { "h": 0.28, "w": 0.25, "x": 0.72, "y": 0.27 }, "kind": "list", "text": "Of the estimated 485K immunocompromised people at highest risk:\n67K: stem cell transplants\n86K: solid organ transplants (liver/lung/kidney)\n332K: hematologic/lymphatic cancers", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.915+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "35d643fb-0cfd-44e9-985f-501ae130eb79", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.25, "x": 0.72, "y": 0.605 }, "kind": "list", "text": "Care for these populations is often associated with specialized centers", "attrs": null, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.915+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "9ab3e36d-44d7-470c-b831-a19ea11e8913", "parentComponentId": null }, { "bbox": { "h": 0.02, "w": 0.44, "x": 0.049, "y": 0.229 }, "kind": "paragraph", "text": "Estimated U.S. total addressable market (TAM)", "attrs": null, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.915+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "f73d5ec9-1a53-459c-9fc4-34181dc3c252", "parentComponentId": null }, { "bbox": { "h": 0.035, "w": 0.79, "x": 0.049, "y": 0.943 }, "kind": "source-note", "text": "Reference: Illustrative graph and estimated market opportunity based on Invivyd-sponsored market research and internal analysis. PrEP: Pre-exposure prophylaxis; RA: rheumatoid arthritis; IBD: inflammatory bowel disease; MS: multiple sclerosis; HIV: human immunodeficiency virus; HCP: Health care professional", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.915+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "4a7cbd6c-e127-4ef7-929c-408867651e78", "parentComponentId": null }, { "bbox": { "h": 0.07, "w": 0.901, "x": 0.049, "y": 0.065 }, "kind": "title", "text": "SIGNIFICANT MARKET OPPORTUNITY WITH >9M IMMUNOCOMPROMISED PEOPLE AT INCREASED RISK FOR SEVERE COVID-19 IN THE U.S.", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.915+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "2800fba9-02cc-47cb-8aa5-929f0d721790", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [ { "to": 9, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889", "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction", "position": 0, "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:11:44.892947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 9, "type": "resolution", "function": "plan_implementation", "rawType": "propose_solution", "block": null, "metadata": { "slideType": "propose_solution", "slideTypeCanon": { "name": "Propose solution (contrarian)", "slug": "propose_solution", "status": "active", "canonId": "019de52d-1274-703c-81c6-5550f451697b", "version": 1, "description": null }, "function": "plan_implementation", "functionCanon": { "name": "Plan implementation", "slug": "plan_implementation", "status": "active", "canonId": "019de52d-14a2-77ea-b210-d6a95eed4823", "version": 1, "description": null }, "density": "dense", "densityScore": 63, "componentCount": 5, "textChars": 913, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:54.104+00", "seconds": 4.234, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/9", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-9", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.11, "w": 0.86, "x": 0.07, "y": 0.79 }, "kind": "image", "text": "COMIRNATY (COVID-19 Vaccine, mRNA)\nTivicay (dolutegravir) tablets 10 mg | 25 mg | 50 mg\nTriumeq dolutegravir/abacavir/lamivudine\nFetroja (cefiderocol) for injection\nMENVEO Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CR M197 Conjugate Vaccine\nOnce-A-Day CUBICIN (daptomycin for injection", "attrs": {}, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo grid", "slug": "logo-grid", "status": "active", "canonId": "019de52c-fdd7-7409-93e5-81280a8ca215", "version": 1, "description": null }, "framework": null }, "subkind": "logo-grid", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.104+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5092d056-5eb2-48bd-bf47-a1716524128d", "parentComponentId": null }, { "bbox": { "h": 0.309, "w": 0.869, "x": 0.055, "y": 0.254 }, "kind": "list", "text": "Go-to-market planning (e.g., market research, market sizing/segmentation, brand strategy, field force sizing)\nMarket access activities (e.g., payer/pricing research, distribution channels)\nManufacturing initial commercial inventory\nEstablishing necessary internal systems and technology to support the transition to commercial stage", "attrs": {}, "canon": { "kind": { "name": "List", "slug": "list", "status": "active", "canonId": "019de52c-f94b-779b-a53b-fd4904a5f4d2", "version": 1, "description": "Bullet or numbered list." }, "tool": null, "subkind": { "name": "Bullet list", "slug": "bullet", "status": "active", "canonId": "019de52c-fc98-7169-a083-5cab805076ca", "version": 1, "description": null }, "framework": null }, "subkind": "bullet", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.104+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "20416dd3-fb1e-4b15-a079-a4d14d317728", "parentComponentId": null }, { "bbox": { "h": 0.05, "w": 0.783, "x": 0.107, "y": 0.673 }, "kind": "paragraph", "text": "Commercial preparations are being led by a seasoned team with extensive experience successfully commercializing products within the infectious disease space, such as:", "attrs": {}, "canon": { "kind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "5f2affc0-941d-4d07-959d-4bfc1930cea4", "version": 1, "description": "Single prose block in the body of a slide." }, "tool": null, "subkind": { "name": "Paragraph", "slug": "paragraph", "status": "active", "canonId": "019de52c-fb80-75af-aa5c-a7a4bfac2433", "version": 1, "description": null }, "framework": null }, "subkind": "paragraph", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.104+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "31379fc1-114b-4120-8019-0c76db8144fb", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.07, "x": 0.85, "y": 0.954 }, "kind": "source-note", "text": "INVIVYD", "attrs": {}, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.104+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "67db183f-99f6-4649-94b2-933c9eef374c", "parentComponentId": null }, { "bbox": { "h": 0.08, "w": 0.889, "x": 0.045, "y": 0.063 }, "kind": "title", "text": "COMMERCIALIZATION PREPARATIONS ARE UNDERWAY FOR POTENTIAL VYD222 LAUNCH IN THE U.S., IF AUTHORIZED", "attrs": {}, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.104+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "bd2b95fc-2d8d-4967-a6c9-1737fa316956", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null }, "from": 9, "name": "Action", "beatId": "feb56317-a2e6-4f8a-8b39-db8ce0bbaf5d", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Action", "slug": "monroes-sequence-action", "status": "active", "canonId": "019dd9b8-181e-760d-befc-010c2424fa89", "version": 1, "description": null }, "evidence": "The commercialization preparations and financial overview outline the next steps", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [ { "to": 9, "from": 5, "loop": { "name": "27_cost_of_inaction", "slug": "27-cost-of-inaction", "status": "active", "bestFor": "Urgent budget requests, compliance, risk mitigation", "canonId": "019dd956-70d1-7395-a15b-857ba858b394", "version": 1, "bodyDocId": "019df22a-2420-77be-bc41-ded96d08cb21", "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point", "description": "Quantify what happens if the audience does nothing", "familyLabel": null }, "matchId": "d0bf14cf-88e0-4c86-bb16-82a24eeb0889", "evidence": "The presentation highlights the urgent need for protection and the potential consequences of inaction", "position": 0, "objective": "What is the cost of not protecting immunocompromised individuals from COVID-19?", "confidence": 0.7, "extraction": { "at": "2026-07-16 23:11:44.892947+00", "model": "or:meta-llama/llama-4-scout", "runId": null, "seconds": null, "promptVersion": "doc-narrative-v1" } } ], "locked": true }, { "page": 10, "type": "setup", "function": "summarize", "rawType": "kpi_overview", "block": null, "metadata": { "slideType": "kpi_overview", "slideTypeCanon": { "name": "KPI overview (contrarian)", "slug": "kpi_overview", "status": "active", "canonId": "019de52d-11d5-7328-b1d1-5368a03e7796", "version": 1, "description": null }, "function": "summarize", "functionCanon": { "name": "Summarize", "slug": "summarize", "status": "active", "canonId": "019de52d-1541-704f-b86f-bf7b75056373", "version": 1, "description": null }, "density": "balanced", "densityScore": 40, "componentCount": 4, "textChars": 291, "nDataPoints": 2, "notes": null, "elementsJson": null, "confidence": 0.9, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:54.44+00", "seconds": 4.045, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/10", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-10", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.18, "w": 0.401, "x": 0.539, "y": 0.436 }, "kind": "callout", "text": "Expected cash runway remains into Q4 2024, excluding potential contribution from commercial product revenue if a mAb candidate is authorized or approved", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.44+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "22ce9bfd-6e90-44aa-849f-782a62352a42", "parentComponentId": null }, { "bbox": { "h": 0.119, "w": 0.379, "x": 0.101, "y": 0.46 }, "kind": "callout", "text": "Cash, cash equivalents and marketable securities were $264.9 million as of September 30, 2023", "attrs": null, "canon": { "kind": { "name": "Callout", "slug": "callout", "status": "active", "canonId": "019de52c-f8d3-761a-8953-7d37080de5e2", "version": 1, "description": "Highlighted callout box." }, "tool": null, "subkind": { "name": "Primary callout", "slug": "primary", "status": "active", "canonId": "019de52c-fbd1-70eb-a9ce-8997f8674c1d", "version": 1, "description": null }, "framework": null }, "subkind": "primary", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.44+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5476a416-bf91-4447-9889-b623fc73e329", "parentComponentId": null }, { "bbox": { "h": 0.015, "w": 0.139, "x": 0.044, "y": 0.923 }, "kind": "source-note", "text": "mAb: monoclonal antibody", "attrs": null, "canon": { "kind": { "name": "Source note", "slug": "source-note", "status": "active", "canonId": "23484952-494b-4a5e-b1ad-550d0d70e948", "version": 1, "description": "Attribution / source / caveat placed at the slide footer. Numbered footnotes use attrs.numbered." }, "tool": null, "subkind": null, "framework": null }, "subkind": null, "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.44+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "5a253c25-1681-4247-84a1-9338388de60c", "parentComponentId": null }, { "bbox": { "h": 0.039, "w": 0.499, "x": 0.042, "y": 0.104 }, "kind": "title", "text": "KEY Q3 2023 FINANCIALS", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:54.44+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "ab8c9df5-bffc-46c6-948b-e25b1b060622", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [ { "to": 10, "arc": { "name": "Monroe's Motivated Sequence", "slug": "monroes-sequence", "status": "active", "bestFor": "Persuasive speeches, call-to-action decks", "canonId": "019dd956-5f25-7189-a428-2e6d7f9e5606", "version": 1, "bodyDocId": "019df22a-2356-73eb-8061-d8c81dc0aa49", "structure": "Attention -> Need -> Satisfaction -> Visualization -> Action", "description": null, "familyLabel": null }, "from": 9, "name": "Action", "beatId": "feb56317-a2e6-4f8a-8b39-db8ce0bbaf5d", "matchId": "650251c1-b459-4ce8-86b5-42ca4decd3c6", "beatType": { "name": "Action", "slug": "monroes-sequence-action", "status": "active", "canonId": "019dd9b8-181e-760d-befc-010c2424fa89", "version": 1, "description": null }, "evidence": "The commercialization preparations and financial overview outline the next steps", "position": 3, "isPrimaryArc": true, "parentBeatType": { "name": "Resolution", "slug": "resolution", "status": "active", "canonId": "019dd9b8-045d-703b-8dd7-e92aba3ba91b", "version": 1, "description": "How the deck ends. Required in 19/20 arcs. The exception (Sparkline) ends with new bliss which is functionally a resolution." }, "alignedBlockIds": null, "matchConfidence": 0.8 } ], "loops": [], "locked": true }, { "page": 11, "type": "appendix", "function": "filler", "rawType": "other", "block": null, "metadata": { "slideType": "other", "slideTypeCanon": { "name": "Other (fallback)", "slug": "other", "status": "active", "canonId": "019de52d-0af5-71ed-83de-d51ae245fc43", "version": 1, "description": null }, "function": "filler", "functionCanon": { "name": "Filler", "slug": "filler", "status": "active", "canonId": "019de52d-1568-702b-ad12-428490978783", "version": 1, "description": null }, "density": "sparse", "densityScore": 3, "componentCount": 2, "textChars": 16, "nDataPoints": 0, "notes": null, "elementsJson": null, "confidence": 1, "extraction": { "model": "google/gemini-2.5-flash", "runId": null, "at": "2026-05-02 07:44:53.343+00", "seconds": 2.788, "promptVersion": "v2-canon-conditioned" } }, "links": { "slide": "/slides/019de517-1302-72c9-b1b1-402f68725e8a/11", "deck": "/decks/019de517-1302-72c9-b1b1-402f68725e8a", "deckAnchor": "/decks/019de517-1302-72c9-b1b1-402f68725e8a#slide-11", "deckJson": "/decks/019de517-1302-72c9-b1b1-402f68725e8a.json" }, "components": [ { "bbox": { "h": 0.049, "w": 0.212, "x": 0.394, "y": 0.166 }, "kind": "image", "text": "INVIVYD", "attrs": null, "canon": { "kind": { "name": "Image", "slug": "image", "status": "active", "canonId": "019de52c-f978-701f-a720-51d029d769e7", "version": 1, "description": "Photo, illustration, screenshot or icon." }, "tool": null, "subkind": { "name": "Logo", "slug": "logo", "status": "active", "canonId": "019de52c-fdaf-743d-94c4-d7c6a0e55302", "version": 1, "description": null }, "framework": null }, "subkind": "logo", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.343+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "b6f9a147-9585-4d04-935f-9ccf3d6a7706", "parentComponentId": null }, { "bbox": { "h": 0.06, "w": 0.402, "x": 0.299, "y": 0.447 }, "kind": "title", "text": "THANK YOU", "attrs": null, "canon": { "kind": { "name": "Title", "slug": "title", "status": "active", "canonId": "019de52c-f7dd-76d9-b848-b1f12bd85cf4", "version": 1, "description": "Slide title or headline." }, "tool": null, "subkind": { "name": "Headline", "slug": "headline", "status": "active", "canonId": "019de52c-fae1-7463-9a7c-d60668eced0d", "version": 1, "description": null }, "framework": null }, "subkind": "headline", "groupRole": null, "confidence": null, "extraction": { "at": "2026-05-02 07:44:53.343+00", "model": "google/gemini-2.5-flash", "runId": null, "seconds": null, "promptVersion": null }, "componentId": "596ae78f-081f-4914-88dd-676edef546b4", "parentComponentId": null } ], "metrics": [], "tools": [], "frameworks": [], "arcBeats": [], "loops": [], "locked": true } ], "arcBeats": [ { "from": 1, "to": 1, "label": "Attention", "description": "The cover slide grabs attention with a clear title and agenda" }, { "from": 5, "to": 5, "label": "Need", "description": "The problem statement highlights the urgent need for protection against COVID-19" }, { "from": 6, "to": 7, "label": "Visualization", "description": "The comparison table and roadmap provide a clear visualization of VYD222's potential" }, { "from": 9, "to": 10, "label": "Action", "description": "The commercialization preparations and financial overview outline the next steps" } ], "loops": [ { "from": 5, "to": 9, "label": "Cost Of Inaction", "description": "What is the cost of not protecting immunocompromised individuals from COVID-19?" }, { "from": 1, "to": 3, "label": "Why Now", "description": "Why is now the right time for VYD222?" } ] }